[HTML][HTML] Emerging therapies for non-small cell lung cancer
Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
[HTML][HTML] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …
Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer
C Aggarwal, JC Thompson, TA Black, SI Katz… - JAMA …, 2019 - jamanetwork.com
Importance The clinical implications of adding plasma-based circulating tumor DNA next-
generation sequencing (NGS) to tissue NGS for targetable mutation detection in non–small …
generation sequencing (NGS) to tissue NGS for targetable mutation detection in non–small …
High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor …
R Benayed, M Offin, K Mullaney, P Sukhadia… - Clinical Cancer …, 2019 - AACR
Purpose: Targeted next-generation sequencing of DNA has become more widely used in
the management of patients with lung adenocarcinoma; however, no clear mitogenic driver …
the management of patients with lung adenocarcinoma; however, no clear mitogenic driver …
Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
D Planchard, S Popat, K Kerr, S Novello… - Annals of …, 2019 - annalsofoncology.org
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
[HTML][HTML] Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed …
The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …
[HTML][HTML] Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience
Introduction Mutations in the KRAS gene are the most common driver oncogenes present in
lung adenocarcinomas. We analyzed the largest multi-institutional database available …
lung adenocarcinomas. We analyzed the largest multi-institutional database available …
[HTML][HTML] HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang, S Yang… - Annals of …, 2019 - Elsevier
Background Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision …
NA Pennell, A Mutebi, ZY Zhou, ML Ricculli… - JCO Precision …, 2019 - ascopubs.org
PURPOSE The aim of the current study was to assess the economic impact of using next-
generation sequencing (NGS) versus single-gene testing strategies among patients with …
generation sequencing (NGS) versus single-gene testing strategies among patients with …
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) have significantly benefited
from the use of EGFR tyrosine kinase inhibitors (TKIs). However, long-term efficacy of these …
from the use of EGFR tyrosine kinase inhibitors (TKIs). However, long-term efficacy of these …